Moderna Inc (MRNA)

Oct 28, 2025

US health agency fires official who opposed mRNA Covid shots - MarketScreener

Oct 28, 2025

Oct 28, 2025

New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle

Oct 28, 2025

Oct 28, 2025

AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat

Oct 28, 2025

Oct 28, 2025

Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat

Oct 28, 2025

Oct 28, 2025

How Moderna Inc. stock trades before earningsWatch List & Community Verified Swing Trade Signals - newser.com

Oct 28, 2025

Oct 27, 2025

Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará

Oct 27, 2025

Oct 27, 2025

Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks

Oct 27, 2025

Oct 27, 2025

Will Moderna Inc. stock see insider buyingJuly 2025 Snapshot & Low Drawdown Trading Techniques - Fundação Cultural do Pará

Oct 27, 2025

Oct 27, 2025

Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360

Oct 27, 2025

Oct 27, 2025

What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com

Oct 27, 2025

Oct 27, 2025

Best data tools to analyze Moderna Inc. stockDollar Strength & Growth Oriented Trade Recommendations - newser.com

Oct 27, 2025

Oct 27, 2025

Using economic indicators to assess Moderna Inc. potentialTrade Ideas & Real-Time Price Movement Reports - newser.com

Oct 27, 2025

Oct 27, 2025

Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com

Oct 27, 2025

Oct 27, 2025

D.A. Davidson & CO. Purchases 62,778 Shares of Moderna, Inc. $MRNA - MarketBeat

Oct 27, 2025

Oct 27, 2025

Why Moderna Inc. stock is favored by top institutionsJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com

Oct 27, 2025

Oct 27, 2025

Is Moderna Inc. stock in correction or buying zonePortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com

Oct 27, 2025

Oct 27, 2025

Analysts Set Expectations for Moderna FY2026 Earnings - MarketBeat

Oct 27, 2025

Oct 27, 2025

FY2026 EPS Estimates for Moderna Lowered by Analyst - MarketBeat

Oct 27, 2025

Oct 27, 2025

Equities Analysts Issue Forecasts for Moderna Q3 Earnings - MarketBeat

Oct 27, 2025

Oct 27, 2025

Moderna (NASDAQ:MRNA) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat

Oct 27, 2025

Oct 27, 2025

Is it too late to sell Moderna Inc.IPO Watch & Accurate Entry and Exit Point Alerts - newser.com

Oct 27, 2025

Oct 26, 2025

Moderna scraps mRNA vaccine in congenital CMV on trial failure - Medical Dialogues

Oct 26, 2025

Oct 25, 2025

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Daily News Journal

Oct 25, 2025

Oct 25, 2025

VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Moderna, Inc. $MRNA - MarketBeat

Oct 25, 2025

Oct 25, 2025

How moving averages guide Moderna Inc. trading2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com

Oct 25, 2025

Oct 25, 2025

Moderna to Host Investor Event – Analyst Day - Shelby Star

Oct 25, 2025

Oct 25, 2025

Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Bluffton Today

Oct 25, 2025

Oct 24, 2025

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Pueblo Chieftain

Oct 24, 2025

Oct 24, 2025

Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Oct 24, 2025

Oct 24, 2025

JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat

Oct 24, 2025

Oct 24, 2025

Moderna (NASDAQ:MRNA) Shares Gap Down Following Analyst Downgrade - MarketBeat

Oct 24, 2025

Oct 24, 2025

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Daily Jeffersonian

Oct 24, 2025

Oct 24, 2025

UBS Maintains Moderna (MRNA) Buy Recommendation - Nasdaq

Oct 24, 2025

Oct 24, 2025

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Holland Sentinel

Oct 24, 2025

Oct 23, 2025

How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo Finance

Oct 23, 2025

Oct 23, 2025

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Asheville Citizen Times

Oct 23, 2025

Oct 23, 2025

Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance

Oct 23, 2025

Oct 23, 2025

UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Ra - GuruFocus

Oct 23, 2025

Oct 23, 2025

Moderna’s cytomegalovirus vaccine fails a phase III - BioWorld MedTech

Oct 23, 2025

Oct 23, 2025

Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely - Citeline News & Insights

Oct 23, 2025

Oct 23, 2025

Moderna (NASDAQ: MRNA) earns 11th straight Top Employer ranking in Science’s 2025 survey - Stock Titan

Oct 23, 2025